Latest News from EarliTec
NEWS
EarliPoint is a fairly new device that uses eye-tracking technology to help pinpoint if a child as young as 16 months is on the autism spectrum.
Called the EarliPoint Evaluation, it has been authorized for use with children between the ages of 16-30 months to “aid in the diagnosis and assessment of autism.”
Called the EarliPoint Evaluation, it has been authorized for use with children between the ages of 16-30 months.
EarliPoint is a fairly new device that uses eye-tracking technology to help pinpoint if a child as young as 16 months is on the autism spectrum.
PODCASTS
Dr. Hanna Rue and Jonathan Lehmann join us to discuss the importance of early diagnosis and the potential of a new tool aimed at addressing health disparities, particularly for families from diverse backgrounds. In this episode, we explore the application of the EarliPoint device, which uses eye gaze tracking technology to diagnose autism in children aged 16 to 30 months. Dr. Hanna Rue emphasizes, “We all know that access to diagnostics can be extremely challenging. Within the Boston area, some families are waiting three years. Research supports that the earlier you start with services, the better outcomes you have.”
This week, we were joined by Dr. Ami Klin, the Director of the Marcus Autism Center and a leading expert in autism research. We discussed his groundbreaking work with Dr. Warren Jones, utilizing eye-tracking technology to visualize and measure social engagement in individuals with autism.
Dr. Ami Klin, Director of the Marcus Autism Center at Emory University School of Medicine and Children’s Healthcare in Atlanta, joins David to discuss autism, including prevalence, diagnosis, causes, treatment, and much more.
MEDICAL LECTURES
The American Academy of Pediatrics Guidelines call for universal autism and development delay screenings at 18 and 24 months, yet the median age of ASD diagnosis in the U.S. is still around five years of age.
Dr. Ami Klin (Marcus Autism Center/EarliTec Diagnostics) provides the highlights of the journey to the EarliPoint diagnostic tools, which started over 25 years ago when the field began exploring eye gaze patterns in autism.
NEWS & EVENTS
• Funding round led by Nexus NeuroTech Ventures and Venture Investors Health Fund • New investment will...
Data show that the clinically-validated, FDA-authorized EarliPointTM Evaluation for autism can provide...
The second generation of EarliPoint™ Evaluation uses a tablet to aid clinicians in diagnosing and assessing...
First FDA-cleared tool to assist clinicians in diagnosing and assessing autism in children as young as...
EarliTec Diagnostics Announces $19.5 Million Financing to Advance Autism Diagnosis and Treatment in Children...